Affini-T Therapeutics Email Format

Biotechnology ResearchMassachusetts, United States51-200 Employees

Affini-T is a leading clinical stage precision immunotherapy company targeting oncogenic driver mutations, beginning with KRAS, to develop potentially curative therapies for patients with solid tumors.  We are advancing two distinct T Cell Receptor (TCR) based therapeutic modalities encompassing adoptive cellular therapies and bispecific T Cell Engagers, each designed to harness T cell immunity with unprecedented precision and potency against solid tumors. Our most advanced TCR T-cell therapies are built based on state-of-the-art engineering, synthetic biology, and gene editing proprietary platforms overcoming the challenges of addressing solid tumors. Our T Cell therapies have high specificity and the multi-faceted ability to strike and persist within the solid tumors.  Building on the world-class innovation inherent in our leadership team, founders and differentiating technologies, we are powered to develop transformational medicines that last.

Sign up for free to view info

Company overview Employee directory